Race
As phenotype derives from the expression of genotype, racial differences in therapeutic response are likely based on differences in neurohormonal mechanisms and genetic profiles. Some studies have described racial differences in response to heart failure therapy (Table 1) . However, these data should be interpreted with caution, as most studies were either small or retrospective in nature.
Sex differences
Sex-related differences have been described in patients with heart failure. Women tend to have different clinical characteristics, heart failure etiology and biomarker profiles than men. [11] [12] [13] [14] [15] The female sex hormone estrogen also has significant effects on several aspects of cardiac physiology. 16 Therefore, sex-related differences in drug response may be expected, as illustrated by retrospective analyses by the Digitalis Investigation Group trial (Table 1) . 6 Heart failure etiology
Ischemic heart failure and non-ischemic heart failure arise from different pathophysiological mechanisms, therefore their response to treatment may also differ. 17 Determining etiology may help in selecting initial drug therapy in some cases, e.g. bromocriptine as potential therapy for acute severe peripartum cardiomyopathy 18 or iron chelation as treatment for seconary iron-overload cardiomyopathy. 19 Variable response to β-blockers, Angiotensin Converting Enzyme (ACE)-inhibitors, calcium antagonists and phosphodiesterase 3 inhibitors has been described in patient groups with different heart failure etiologies. 7, 17 Although most of these observations are drawn from subgroup analyses, they underscore the potential for such differential treatment effects.
Heart failure with reduced vs. preserved ejection fraction
Pharmacological interventions with proven efficacy in heart failure with reduced ejection fraction (HFrEF) have failed to improve morbidity and mortality in heart failure with preserved ejection fraction (HFpEF). 20 Of particular interest are the marked differences in outcomes between HFrEF and HFpEF in studies with Renin Angiotensin Aldosterone System (RAAS)-inhibiting agents (Table 1) . Treatment with ACE-inhibitors, for example -a cornerstone in the management of heart failure -did not result in reduced mortality or heart failure hospitalization in patients with HFpEF. 8 Similar disappointing results were recently presented for the mineralocorticoid receptor antagonist spironolactone -another key evidence-based heart failure therapy -during late-breaking clinical trial sessions at the 2013 American Heart Association Congress (TOPCAT). 85 The observed differences in therapeutic response between patients with 1 
Atrial fibrillation
While treatment with β-blockers has been shown to reduce mortality and morbidity in patients with heart failure 1 , no such benefit was seen in heart failure patients with atrial fibrillation. [21] [22] [23] [24] [25] There is some evidence from retrospective studies that patients in sinus rhythm profit more from treatment with β-blocker than patients with atrial fibrillation, though this has yet to be confirmed in properly designed, prospective clinical trials. [21] [22] [23] [24] [25] Heart failure guidelines still recommend β-blockers as first-line treatment in patients with atrial fibrillation.
geNeTICs
The exploration of the human genome [26] [27] [28] and ongoing developments in genomics allow us to study differential gene expression patterns in the development of heart failure. Genome-wide association studies allow rapid scanning of the genome for small variations and determination of whether these single nucleotide polymorphisms (SNPs) are associated with phenotype. Several genes have been identified with greater expression in certain cardiomyopathies, such as dilated cardiomyopathy 29 and hypertrophic cardiomyopathy 30 . In current clinical practice, genetic testing is used to identify relatives of patients with a mutation-associated cardiomyopathy who are also at risk of developing it but do not express the phenotype, to diagnose metabolic/ myocardial storage diseases mimicking hypertrophic cardiomyopathy, and for immunodiagnostics and immunomonitoring in heart transplants (e.g. AlloMap® testing). 31 However, the growing use of genomic data is associated with a number of ethical and privacy issues. Genome sequencing may reveal information about the health of participants and their families, while its significance is not always clear-cut. Current developments -including gene patenting and privacy concerns -demand updated ethical and legal frameworks, and should be addressed by medical professionals, patients, policy makers, and governments.
Pharmacogenetics
Pharmacogenetics is the study of the effects of genomic polymorphisms on clinical drug response. The importance of applying genomic testing to the evaluation of therapy response was first recognized in oncology. 32, 33 In cardiology, several genetic variations have been shown to be associated with differential response to therapy (Table 2) . These examples illustrate how genomic polymorphisms may aid in identifying responders and non-responders.
Adrenergic receptor polymorphisms
Several pharmacogenetic effects of adrenergic receptor polymorphisms on response to heart failure therapy have been described (Table 2 ). Variance in β 1 -, β 2 -and α 2c -adrenergic receptor have been shown to be associated with differential response to β-blocker therapy. [34] [35] [36] [37] [38] [39] These studies underscore that genetic variation may play a role in response variability. It should be stressed, however, that most findings were obtained via retrospective analyses and as a whole do not provide sufficient evidence to guide treatment based on genetic testing. Prospective research is required to determine whether these findings are replicable.
Genetic variation in the angiotensin converting enzyme
ACE gene insertion/deletion (I/D) polymorphisms have been associated with the level of enzyme activity, with allele deletion resulting in higher levels of ACE. 40 Thus, ACE D/D carriers have higher RAAS activity. Several studies suggested that the ACE D/D variant is associated with the development of heart failure and a poorer prognosis in patients with manifest heart failure. 41, 42 Therapeutic response to ACE-inhibitors is 
Endothelin-1
Endothelin-1, a potent vasoconstrictor peptide expressed by vascular endothelium and cardiomyocytes, promotes cardiomyocyte contractility and hypertrophy. 44 After the β-blocker evaluation of Survival Trial (BEST) 45 was terminated early, data became available to serve as a resource for studies investigating genetic interactions. In bucindolol-treated patients, two SNPs in the endothelin-1 gene , the G/A IVS-4 variant and Lys198Asn variant that are in tight linkage disequilibrium, were found to be associated with prognosis. 46 However, the exact role of these SNPs in this pharmacogenetic interaction remains to be clarified by future research.
Candidate genes associated with chemotherapeutic cardiotoxicity
Cardiotoxicity is a serious adverse drug reaction to several chemotherapeutic agents, such as doxorubicin and trastuzumab (Herceptin). 47, 48 Current options for predicting the risk of chemotherapy-induced cardiotoxicity are limited. Several candidate genes have been associated with the risk of chemotherapeutic cardiotoxicity. Some gene variants have been associated with an increased risk; for example, genetic polymorphisms encoding NAPDH oxidase and doxorubicin efflux transporter ABCB1/MDR1 and variance in the HER2 genotype (Ile/Val) are associated with an increased the risk of developing cardiotoxicity. 49, 50 Other gene variants were found to be protective; in children, a variant in the SLC28A3 gene was associated with protection against cardiotoxicity.
51

PRoTeoMICs aND BIoMaRKeRs
Previously mentioned studies illustrate how genomic mapping may contribute to identifying responders and non-responders. However, as one gene can code for multiple proteins, biomarkers may provide additional information. In recent years, the investigation of heart failure-related biomarkers has increased exponentially. 52 Most studies examine the prognostic implication of biomarkers. 52 However, several biomarkers have also been shown to be related to drug response. The following examples illustrate how knowledge certain biomarkers levels can be used to determine drug response and to monitor treatment.
Pre-treatment biomarkers levels and therapeutic response
Plasma renin activity ACE-inhibitors have been shown to be more effective in patients with higher pretreatment plasma renin activity (PRA). 53, 54 In heart failure patients, the effects of ACEinhibition were greater in individuals with high pre-treatment renin levels. 54 These results imply that patients with higher neurohormonal activity would respond better to neurohormonal blocking agents, and underline the potential value of assessing pre-treatment levels of substances blocked by specific therapies. It should be noted however that there are studies suggesting that determining PRA prior ACE-inhibitor treatment would only be helpful in Caucasian populations. 55 
Arginine vasopressine
Tolvaptan, an arginine vasopressine (AVP) antagonist, had no overall effect on morbidity and mortality in heart failure patients. 56 Studying pre-treatment AVP levels did not reveal heterogeneity in treatment response. 57 However, the instability and rapid metabolism of AVP may have complicated these analyses. 58 Copeptin, the C-terminal portion of pro-AVP, is more stable and easy to measure, and has therefore been proposed as a reliable biomarker that mirrors AVP levels. 58 A phase III randomized clinical trial investigating the therapeutic efficacy of tolvaptan in patients with high copeptin levels is currently ongoing (ACTIVATE, NCT01733134).
Cardiac extracellular matrix markers
Procollagen type I amino-terminal peptide (PINP), procollagen type I carboxy-terminal peptide (PICP), and plasma procollagen type III amino-terminal peptide (PIIINP) are markers of collagen synthesis and can be used to monitor cardiac extracellular matrix (ECM) turnover. In one post-hoc study, heart failure patients with high baseline ECM levels experienced a greater benefit from treatment with spironolactone. 
Biomarker-guided therapy
Natriuretic peptides
Brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are the most studied biomarkers for biomarker-guided therapy. Results on efficacy are conflicting, with some studies confirming initial positive findings, [60] [61] [62] [63] while others yielded negative results. [64] [65] [66] [67] [68] [69] In a meta-analysis, natriuretic peptide-guided therapy was associated with a significantly lower risk of all-cause mortality and heart failure hospitalization 1 compared with usual clinical care. 70 A large, randomized clinical trial comparing usual care with NT-proBNP guided care is ongoing (GUIDE-IT, NCT01685840).
Hemoconcentration
Hemoconcentration, defined as increasing hematocrit, is considered a surrogate marker for changes in intravascular volume status during fluid extraction. 71, 72 Therefore, hemoconcentration can be used to gauge the effectiveness of diuretic therapy in acute decompensated heart failure. Several studies have shown that hemoconcentration is associated with improved outcomes in heart failure.
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MicroRNAs
MicroRNA (MiRNA) are small, non-coding RNAs that regulate protein expression by inhibiting translation or promoting degradation of target messenger RNA. 77 Several different miRNA expression patterns associated with the development of heart failure have been described. 78 miRNA are also proving worthwhile potential therapeutic targets. MiRNA mimics and antisense miRNA oligonucleotides may restore miRNA levels by replacing or inhibiting miRNA activity, respectively. 79 Some miRNAs are also detectable in peripheral tissue, such as blood and urine, and could be used to monitor heart failure therapy. 80 A recent animal study by Dickinson et al. found that circulating miRNA levels change in response to treatment, indicating miRNA levels could be helpful in monitoring heart failure treatment.
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FuTuRe PeRsPeCTIves
We have presented several studies exemplifying how certain pre-treatment clinical information may assist in determining drug response. However, the underlying question this approach seeks to answer is: 'How can we distinguish potential responders from non-responders?' An answer to this question requires in-depth understanding of the complex biological interactions in heart failure. Systems biology is an emerging approach that reaches beyond reductionism, in which every structure and function of genes and proteins is studied in isolation. The foundation of systems biology is the concept that genes and proteins act in concert in complex networks that result in organizational units, and focuses on the study of higher order interactions between fundamental biological elements which determine the expression and appearance of health and disease. A large, prospective observational study employing a systems biology approach -including clinical, laboratory, genomic and proteomic data -to evaluate which heart failure patients have poor clinical outcomes despite proven evidence-based heart failure therapy is currently underway (BIOSTAT-CHF, http://www.biostatchf.eu/). The identification of responder and non-responder profiles in BIOSTAT-CHF and other studies should always be followed by prospective randomized clinical trials to confirm hypotheses. In addition, we believe that development programs for novel heart failure drugs should include responder/non-responder analyses. For logistical and practical reasons, such analyses can only be based on surrogate endpoints, and should also be based on biological plausibility. The first step in testing this approach would be retrospective, hypothesis-generating analyses in previously conducted randomized trial populations, comparing pre-defined responder and non-responder profiles and examining associations between these profiles clinical outcomes. Observed pathogenic associations may thus lay the groundwork for further research to identify responders and non-responders. The ultimate goal is the development of a risk stratification model to distinguish between the two groups prior to treatment. Current studies define the patient population of interest at an early stage, based solely on assumptions. We are of the opinion that phase II studies should include a wider variety of patients in order to not only establish the correct dose, but also identify the right patient, based in part on a systems biology approach. This will increase the likelihood of success in phase III trials.
In conclusion, there is a pressing need to distinguish responders from non-responders to pharmacological therapy in an early phase. Investigations in this direction should not be limited to clinical characteristics alone, but may be greatly enhanced by genomic and proteomic information. Using the full breadth of available data in designing future studies may result in a more targeted approach, leading to larger effects in responders while minimizing needless therapy in non-responders, serving the ultimate goal of improved personalized treatment for each and every patient.
